



Brinsupri[®]

(brensocatib) tablets, 10mg·25mg

Instructions to create a patient list to identify patients aged 12 years and older with a diagnosis of non-cystic fibrosis bronchiectasis in the Epic[®] EHR system

INDICATION

BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Dermatologic Adverse Reactions

Treatment with BRINSUPRI is associated with an increase in dermatologic adverse reactions, including rash, dry skin, and hyperkeratosis. Monitor patients for development of new rashes or skin conditions and refer patients to a dermatologist for evaluation of new dermatologic findings.

Gingival and Periodontal Adverse Reactions

Treatment with BRINSUPRI is associated with an increase in gingival and periodontal adverse reactions. Refer patients to dental care services for regular dental checkups while taking BRINSUPRI. Advise patients to perform routine dental hygiene.

EHR=electronic health record.



Please see additional Important Safety Information
on last page and full [Prescribing Information](#).

Overview and Limitations

This document is intended to provide health systems with instructions to create a patient list in the Epic® electronic health record (EHR) system to identify patients aged 12 years and older with a diagnosis of non-cystic fibrosis bronchiectasis (NCFB). The instructions are for the Epic EHR system and are not appropriate for other conditions, treatments, or therapeutic areas or for other EHR systems.

The processes outlined in this document are variable, and not all steps will apply to every organization. Any steps or settings that are not part of an organization's standard process should be excluded or modified accordingly. Any questions should be directed to the appropriate service provider. The organization is solely responsible for the implementation, testing, monitoring, and ongoing operation of any EHR tools.

Suggested Patient List Criteria

Consider using the clinical criteria below to help identify patients aged 12 years and older with a diagnosis of NCFB who may be candidates for BRINSUPRI®. The clinical data elements provided are only suggestions, and it is strongly recommended that clinical and operational leadership ensure that the final elements align with the expectations and goals of the organization. Eligibility for treatment and treatment selection are always decisions made by the healthcare provider.

- Age: 12 years and older
- Diagnoses:
 - ICD-10-CM J47.0: Bronchiectasis with acute lower respiratory infection
 - ICD-10-CM J47.1: Bronchiectasis with (acute) exacerbation
 - ICD-10-CM J47.9: Bronchiectasis, uncomplicated
- Treatments for NCFB (antimicrobial medications, airway clearance, pulmonary rehabilitation, etc)

Note: Consider running the report on a regular basis. Once the initial report has been created, it can be saved for future use and subsequent reports can be rerun. Running reports over time helps identify new patients who meet the inclusion criteria.

Instructions

Epic's Reporting Workbench or SlicerDicer may be used to create the patient list. Depending on availability, consider using the preferred reporting tool to complete the patient report. Consult your organization if administrative user rights are required to access the reporting tools.

Option 1: Reporting Workbench

1. Access Reporting Workbench (click the Epic logo > Reports > My Reports).
2. In the search field, enter "generic criteria" and click Search to find the reporting template.
3. Select the Find Patients - Generic Criteria template and click New.
4. In the Report Settings window, select the Criteria tab and add the first criterion to the query.
5. In the Find Criteria search field, enter "age."
6. Select the Age in Years criterion and set the age range to 12 years and older.
7. In the Find Criteria search field, enter "diagnosis" and select the Diagnosis by Code criterion.
8. Enter and select the bronchiectasis diagnoses ICD-10-CM codes J47.0, J47.1, and J47.9.
9. In the Find Criteria search field, enter "medication" and select the Meds: Current, by pharm. class criterion.
10. Enter and select the desired antimicrobial therapies. Consider searching by pharmaceutical class, or enter and select individual medications.
Note: The names may vary depending on the compendium.
11. In the Find Criteria search field, enter "procedures" and select the Procedures criterion.
12. Enter and select the desired procedures (e.g., airway clearance, pulmonary rehabilitation).
Note: The names may vary depending on the organization.
13. Set the logic to include the age, the diagnosis codes, 1 or more antimicrobial therapies, and procedures (if included).
14. Select the Display tab to set all display columns for the report. Select the desired columns and click the right arrow or drag them to the Selected Columns pane. Consider current and past medications, encounter history, and other desired patient information to display in the report.

continued on the next page

Instructions (cont'd)

Option 1: Reporting Workbench (cont'd)

15. In the General tab, enter the desired report name (e.g., "Patients aged 12 years and older with a diagnosis of bronchiectasis on treatments for NCFB") and a description. Results can be shared with selected users or pools.
16. Click Save and then Run to create the patient list. The list will display all patients matching the criteria.

Note: Prior authorization requirements vary by health plan. When reviewing the results of the patient report, consider adjusting the age result filter. Some plans may require that patients aged 18 years and older have 2 or more exacerbations but that adolescents aged 12 to 17 years have 1 or more exacerbations (with the exacerbations requiring antibiotic treatment in the past 12 months).

Option 2: SlicerDicer

1. Access SlicerDicer (click the Epic logo > Reports > SlicerDicer).
2. Depending on availability, select the Patients model (the numbers in the data model box represent the base population and number of records in the data model).
3. In the right-hand column, select the desired patient base (e.g., "All Patients").
Note: First-time users of SlicerDicer may see a tutorial prompted during initial use. Complete the tutorial and continue with the steps below.
4. In the Search for Criteria field, enter "age." Alternatively, the + Browse button can be used. When using the + Browse button, a new screen will display where the filter criterion and inclusion/exclusion status can be selected.
5. Select the Age in Years criterion and set the age range to 12 years and older.
6. In the Search for Criteria field, enter "diagnosis" and select the Diagnosis by Code criterion.
7. Set the mode to ICD/Grouped, and enter and select the bronchiectasis diagnoses ICD-10-CM codes J47.0, J47.1, and J47.9.
8. In the Search for Criteria field, enter "medications" and select the Medications criterion.
9. Enter and select the desired antimicrobial therapies. Consider searching by pharmaceutical class, or enter and select individual medications.
Note: The names may vary depending on the compendium.

continued on the next page

Instructions (cont'd)

Option 2: SlicerDicer (cont'd)

10. In the Search for Criteria field, enter "procedures" and select the Procedures criterion.
11. Enter and select the desired procedures (e.g., airway clearance, pulmonary rehabilitation).
Note: The names may vary depending on the organization.
12. Set the logic to include the age, the diagnosis codes, 1 or more antimicrobial therapies, and procedures (if included).
13. Click the last icon with the detail table in the Visual Option section to see the query results.
14. The results can be exported to Reporting Workbench by right-clicking the bar with the patient results and selecting Show Slice in Reporting Workbench.
15. In Reporting Workbench, select the Display tab to set all display columns for the report. Select the desired columns and click the right arrow or drag them to the Selected Columns pane. Consider current and past medications, encounter history, and other desired patient information to display in the report.
16. In the General tab, enter the desired report name (e.g., "Patients aged 12 years and older with a diagnosis of bronchiectasis on treatments for NCFB") and a description. Results can be shared with selected users or pools.
17. Click Save and then Run to create the patient list. The list will display all patients matching the criteria.

Note: Prior authorization requirements vary by health plan. When reviewing the results of the patient report, consider adjusting the age result filter. Some plans may require that patients aged 18 years and older have 2 or more exacerbations but that adolescents aged 12 to 17 years have 1 or more exacerbations (with the exacerbations requiring antibiotic treatment in the past 12 months).

Notes

- The customer (e.g., physician, medical group, integrated delivery network) shall be solely responsible for the implementation, testing, and monitoring of the instructions to ensure proper orientation in each customer's EHR system
- Capabilities, functionality, and setup (customization) for each EHR system may vary. Insmed Incorporated shall not be responsible for revising the implementation instructions it provides to any customer if the customer modifies or changes its software, or the configuration of its EHR system, after such time as the implementation instructions have been initially provided by Insmed Incorporated
- While Insmed Incorporated tests its implementation instructions on multiple EHR systems, the instructions are not guaranteed to work for all available EHR systems, and Insmed Incorporated shall have no liability thereto. The instructions are current as of January 2026
- While EHRs may assist providers in identifying appropriate patients for consideration of assessment, treatment, and referral, the decision and action should ultimately be decided by a provider in consultation with the patient, after a review of the patient's records to determine eligibility, and Insmed Incorporated shall have no liability thereto
- The instructions have not been designed for, and are not tools and/or solutions for, meeting Advancing Care Information and/or any other quality/accreditation requirement
- All products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Insmed Incorporated or its affiliates

INDICATION

BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Dermatologic Adverse Reactions

Treatment with BRINSUPRI is associated with an increase in dermatologic adverse reactions, including rash, dry skin, and hyperkeratosis. Monitor patients for development of new rashes or skin conditions and refer patients to a dermatologist for evaluation of new dermatologic findings.

Gingival and Periodontal Adverse Reactions

Treatment with BRINSUPRI is associated with an increase in gingival and periodontal adverse reactions. Refer patients to dental care services for regular dental checkups while taking BRINSUPRI. Advise patients to perform routine dental hygiene.

Live Attenuated Vaccines

It is unknown whether administration of live attenuated vaccines during BRINSUPRI treatment will affect the safety or effectiveness of these vaccines. The use of live attenuated vaccines should be avoided in patients receiving BRINSUPRI.

ADVERSE REACTIONS

The most common adverse reactions $\geq 2\%$ in the ASPEN trial included upper respiratory tract infection, headache, rash, dry skin, hyperkeratosis, and hypertension. The safety profile for adult patients with NCFB in WILLOW was generally similar to ASPEN, except for a higher incidence of gingival and periodontal adverse reactions.

Less Common Adverse Reactions

Liver Function Test Elevations

In ASPEN, there was an increase from baseline in average ALT, AST, and alkaline phosphatase levels at all time points from Week 4 through Week 56 in both BRINSUPRI 10 mg and 25 mg arms compared to placebo. The incidence of ALT $>3X$ upper limit of normal (ULN) was 0%, 1.2%, and 0.9%; the incidence

of AST $>3X$ ULN was 0.2%, 0.3%, and 0.5%; and the incidence of alkaline phosphatase $>1.5X$ ULN was 2.5%, 4.1%, and 4.0% in patients treated with placebo and BRINSUPRI 10 mg and 25 mg, respectively.

Skin Cancers

In ASPEN, the incidence of skin cancers among patients treated with BRINSUPRI 10 mg and 25 mg was 0.5% and 1.9%, respectively, compared to 1.1% in placebo-treated patients.

Alopecia

In ASPEN, the incidence of alopecia among patients treated with BRINSUPRI 10 mg and 25 mg was 1.5% and 1.6% respectively, compared to 0.4% in placebo-treated patients.

USE IN SPECIFIC POPULATIONS

Pregnancy: There are no clinical data on the use of BRINSUPRI in pregnant women.

Lactation: There is no information regarding the presence of BRINSUPRI and/or its metabolite(s) in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BRINSUPRI and any potential adverse effects on the breastfed child from BRINSUPRI or from the underlying maternal condition.

Pediatric use: The safety and effectiveness of BRINSUPRI for the treatment of NCFB have been established in pediatric patients aged 12 years and older. Common adverse reactions in pediatric patients aged 12 years and older enrolled in ASPEN were consistent with those in adults. The safety and effectiveness of BRINSUPRI have not been established in pediatric patients younger than 12 years of age.

Please see full [Prescribing Information](#).



© 2026 Insmmed Incorporated. All Rights Reserved.
Insmmed, BRINSUPRI, and inLighten are trademarks of Insmmed Incorporated.
PP-BRIN-US-00572 01/2026

Epic® is a registered trademark of Epic Systems Corporation.

